<code id='F4CEF7FCF2'></code><style id='F4CEF7FCF2'></style>
    • <acronym id='F4CEF7FCF2'></acronym>
      <center id='F4CEF7FCF2'><center id='F4CEF7FCF2'><tfoot id='F4CEF7FCF2'></tfoot></center><abbr id='F4CEF7FCF2'><dir id='F4CEF7FCF2'><tfoot id='F4CEF7FCF2'></tfoot><noframes id='F4CEF7FCF2'>

    • <optgroup id='F4CEF7FCF2'><strike id='F4CEF7FCF2'><sup id='F4CEF7FCF2'></sup></strike><code id='F4CEF7FCF2'></code></optgroup>
        1. <b id='F4CEF7FCF2'><label id='F4CEF7FCF2'><select id='F4CEF7FCF2'><dt id='F4CEF7FCF2'><span id='F4CEF7FCF2'></span></dt></select></label></b><u id='F4CEF7FCF2'></u>
          <i id='F4CEF7FCF2'><strike id='F4CEF7FCF2'><tt id='F4CEF7FCF2'><pre id='F4CEF7FCF2'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:Wikipedia    Page View:1893
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In